MedTrace Logo

Tailoring Treatment in Colorectal Cancer

NCT05401318 · Status: RECRUITING · Type: OBSERVATIONAL · Enrollment: 40

Last updated 2024-08-06

No results posted yet for this study

Summary

In this study, the investigators will establish a reliable method and logistic pipeline for personalized drug testing ex vivo using fresh tumor samples from colorectal cancer (CRC) patients. With this, the investigators aim to develop a novel predictive biomarker of immunotherapy response, by testing combinations of chemotherapies and chimeric antigen receptor (CAR) T cells. Critically, this affects a large subgroup of patients currently not considered to benefit from such treatment. To support the hypothesis, the project will make use of cutting-edge, cell-based functional diagnostics. Individual patients' cancer cells will be screened against a panel of chemotherapies and targeted therapies including CAR T cells, to assess the optimal combination of therapies to induce immunotherapy efficacy in otherwise unresponsive CRC.

Conditions

  • Colorectal Neoplasms

Interventions

PROCEDURE

Tumor tissue sampling for organoid development

Fresh tissue from colorectal tumors will be sampled and cultivated in 3D cultures for drug testing.

Sponsors & Collaborators

  • Oncosyne AS

    collaborator INDUSTRY

  • Oslo University Hospital

    collaborator OTHER

  • University Hospital, Akershus

    lead OTHER

Principal Investigators

  • Sebastian Meltzer, M.D., Ph.D. · University Hospital, Akershus

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2022-03-28
Primary Completion
2025-03-28
Completion
2027-01-01

Countries

  • Norway

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05401318 on ClinicalTrials.gov